Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.56 USD
Change Today +0.0051 / 0.33%
Volume 217.4K
NYMX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

nymox pharmaceutical corp (NYMX) Snapshot

Open
$1.56
Previous Close
$1.55
Day High
$1.58
Day Low
$1.54
52 Week High
08/12/14 - $5.75
52 Week Low
12/12/14 - $0.33
Market Cap
54.5M
Average Volume 10 Days
457.1K
EPS TTM
$-0.08
Shares Outstanding
35.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NYMOX PHARMACEUTICAL CORP (NYMX)

nymox pharmaceutical corp (NYMX) Related Bloomberg News

View More Bloomberg News

nymox pharmaceutical corp (NYMX) Related Businessweek News

No Related Businessweek News Found

nymox pharmaceutical corp (NYMX) Details

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. It offers NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products; and AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. The company’s products under development include NX-1207 for the treatment of benign prostatic hyperplasia, localized prostate cancer, and hepatocellular carcinoma; and NXC-4720, an anti-bacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, as well as for the treatment of urinary tract and other bacterial infections in humans. Its products under development also comprise NXB-4221 for the treatment of chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. The company markets NicAlert and TobacAlert tests through its marketing arm and distributors in North America, Europe, and Asia, as well as TobacAlert through online at tobacalert.com. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Saint Laurent, Canada.

nymox pharmaceutical corp (NYMX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $290.0K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $128.1K
Compensation as of Fiscal Year 2014.

nymox pharmaceutical corp (NYMX) Key Developments

Nymox Pharmaceutical Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Nymox Pharmaceutical Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. The company reported a net income of $1,576,551, or $0.04 per share basic and diluted for the quarter ended March 31, 2015, compared to a net loss of $2,592,816, or $0.07 per share basic and diluted for same period in 2014. The net income in 2015 is attributable to the recognition of $2,508,533 as revenue relating to the upfront payment received from Recordati in December 2010 compared with $654,400 for the quarter ended March 31, 2014. The increase of $1,854,133 in the first quarter of 2015 is due to the fact that the initial estimated service period of five years to recognize the upfront payment was modified following Recordati's termination of the European clinical trial. Consequently, the corporation recognized, as revenue, an amount of $2,508,533 which represented the remaining deferred revenue relating to the upfront payment received in December 2010. Excluding the additional $1,854,133 deferred revenue recognized as revenue, the corporation would have incurred a net loss of $277,582 for the quarter ended March 31, 2015 compared to net loss of $2,592,816 for the same period in 2014. The decrease is mainly due to stock compensation charges of $16,551 in 2015 compared to $1,420,185 in 2014 combined to a reduction of $492,432 in clinical trial expenditures related to NX-1207 studies. Revenues from sales amounted to $75,387 for the quarter ended March 31, 2015, compared to $78,164 for the same period in 2014. Total revenues were $2,583,920 against $732,564 a year ago. Net cash used in operating activities were $411,008 against $1,391,461 a year ago. Net income from operating activities was $1,629,038 against net loss from operations was $2,587,210 a year ago.

Nymox Announces New Prostate Cancer Clinical Trial Results

Nymox Pharmaceutical Corporation announced long-term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040. The new results demonstrate statistically significant (p=0.0067) better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls. Trial participants included 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites. A controlled comparison was conducted of patients who required and received radiation and surgery treatments for their cancer based on blinded post-treatment upgraded evaluations of their pre-treatment initially positive lower grade cancers. The study found that after up to 2.8 years for NX-1207 single-injection treated patients there was a 68.2% reduction compared to controls in the proportion of patients who had upgraded blinded biopsy results in the treated area and went on to require and receive radiation therapy and/or prostatectomy (surgery) (p=0.0067). The new study also found that all instances of surgery or radiation, including elective cases without upgrades, were decreased by 62.7% (p=0.0035) in NX-1207 patients compared to the randomized control group. Long-term clinical outcome is a highly important measure of drug treatment efficacy. Patients were randomized to one of two doses of NX-1207 (2.5 mg or 15 mg) or to active surveillance (control). The drug was injected into the area of the prostate where the cancer was detected and repeat biopsies, serial PSA measurements and long-term follow-up were performed on all patients treated and controls.

Nymox Pharmaceutical Corporation Announces Phase 3 BPH Studies

Nymox Pharmaceutical Corporation announced that the company is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH). This will include new long-term data from Studies NX02-0017 and NX02-0018. The company expects to provide these new pivotal Phase 3 study results in second quarter or early third quarter in 2015. The pivotal U.S. studies NX02-0017 and NX02-0018 were initiated in 2009. Enrollment of NX02-0017 (499 patients randomized) was completed in 2012; enrollment of NX02-0018 (498 patients randomized) was completed in 2013. 973 patients were injected with either NX-1207 2.5 mg (n=582) or saline vehicle alone as control (n=391). At 12 months post-treatment there was no overall top-line statistical significance for the efficacy of treatment in terms of BPH Symptom Score improvement vs controls. The safety profile of NX-1207 was excellent.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NYMX:US $1.56 USD +0.0051

NYMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $48.94 USD +0.34
Amorfix Life Sciences Ltd C$0.05 CAD 0.00
Laboratory Corp of America Holdings $118.68 USD +0.73
OraSure Technologies Inc $6.18 USD -0.01
Quest Diagnostics Inc $75.48 USD +0.25
View Industry Companies
 

Industry Analysis

NYMX

Industry Average

Valuation NYMX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NYMOX PHARMACEUTICAL CORP, please visit www.nymox.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.